•
Jun 30, 2024

LabCorp Q2 2024 Earnings Report

Labcorp's Q2 2024 earnings showcased revenue and EPS growth, driven by organic growth and strategic acquisitions.

Key Takeaways

Labcorp reported a strong second quarter in 2024, with revenue increasing by 6.2% to $3.22 billion and diluted EPS rising to $2.43. The company's performance was driven by organic growth in its base business and contributions from acquisitions. Labcorp has updated its full-year guidance to reflect this strong performance and the acquisition of Invitae.

Revenue increased by 6.2% to $3.22 billion compared to Q2 2023.

Diluted EPS increased to $2.43, up from $1.74 in the same quarter last year.

Adjusted EPS increased to $3.94, compared to $3.42 in Q2 2023.

Free cash flow increased significantly to $432.9 million, compared to $58.2 million in the second quarter of 2023.

Total Revenue
$3.22B
Previous year: $3.03B
+6.2%
EPS
$3.94
Previous year: $3.42
+15.2%
Gross Profit
$864M
Previous year: $842M
+2.6%
Cash and Equivalents
$265M
Previous year: $1.9B
-86.0%
Free Cash Flow
$433M
Previous year: $177M
+144.6%
Total Assets
$16.7B
Previous year: $17.7B
-5.6%

LabCorp

LabCorp

LabCorp Revenue by Segment

Forward Guidance

Labcorp is updating its 2024 full-year guidance to reflect its second-quarter performance, the acquisition of Invitae, and its full-year outlook.

Positive Outlook

  • Revenue range of 6.4% to 7.5%, which includes an Invitae impact of approximately 1.0%.
  • Diagnostics Laboratories revenue growth between 6.9% and 7.9%.
  • Biopharma Laboratory Services revenue growth between 3.7% and 5.0%.
  • Adjusted EPS range of $14.30 to $14.90, includes Invitae dilution of ~$0.40.
  • Free Cash Flow of $0.85 billion to $1.00 billion, which includes Invitae cash usage of ~$150 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income